Welcome to our dedicated page for Nexalin Tech news (Ticker: NXL), a resource for investors and traders seeking the latest updates and insights on Nexalin Tech stock.
Nexalin Technology, Inc. develops non-invasive neurostimulation products based on Deep Intracranial Frequency Stimulation, or DIFS™, for brain-health and mental-health indications. Company news commonly covers peer-reviewed clinical publications, neuroimaging and biomarker data, and research programs addressing insomnia, depression, traumatic brain injury, PTSD, Alzheimer’s disease, dementia-related cognitive decline and ADHD.
Updates also describe the HALO™ Clarity device, the NeuroCare® virtual clinic platform, collaborations with clinical research and academic organizations, FDA engagement, and capital-market communications tied to its Nasdaq-listed common stock.
Nexalin Technology (Nasdaq:NXL) highlighted U.S. House Appropriations Committee report language directing the VA to support more research into non-invasive deep brain neurostimulation for treatment-resistant traumatic brain injury (TBI). The provision, advocated by Nexalin America, aligns with Nexalin’s UC San Diego/VA DIFS™ TBI study and could expand VA research opportunities.
Nexalin (Nasdaq:NXL) closed the acquisition of PONM, the AI-integrated digital health platform behind HALO™ Clarity and Nexalin NeuroCare™, from GreenLight Ventures for $1.3 million, payable in Nexalin shares over time.
The deal gives Nexalin ownership and exclusive rights to software supporting remote patient monitoring, virtual-clinic management, EHR functions and real-time data analytics, already deployed at UC San Diego. The platform underpins Nexalin’s TBI/PTSD military study and is being prepared for a planned 160-participant FDA pivotal trial of HALO™ Clarity for moderate-to-severe insomnia, expected to begin enrollment in Q2 2026. Nexalin and GreenLight also entered a strategic partnership to provide ongoing product, engineering, regulatory and commercial support.
Nexalin (NASDAQ: NXL) published a peer-reviewed study in Psychotherapy and Psychosomatics (online April 20, 2026) reporting statistically significant improvement in sleep quality after four weeks of 15 mA, 77.5 Hz DIFS treatment for chronic insomnia versus sham.
The study showed PSQI reduction from 13.8 to 7.7 (p < 0.001) for active treatment and reported measurable modulation of Default and Salience/Ventral Attention networks, which authors link to a potential mechanism for clinical response.
Nexalin Technology (Nasdaq: NXL) advanced its planned pivotal 160‑participant, randomized, triple‑blinded, sham‑controlled clinical trial of the HALO™ Clarity device for moderate‑to‑severe insomnia, with patient enrollment expected to begin in Q2 2026. The study is intended to support a planned De Novo FDA classification request and is executed with Lindus Health as trial operator. Nexalin cites prior peer‑reviewed data showing statistically significant improvements versus sham and says neuroimaging supports its DIFS™ approach. The company will provide further updates on site activation and enrollment timing.
Nexalin Technology (Nasdaq: NXL) completed high-level U.S. and China meetings and a productive Q-Submission interaction with the FDA to shape its De Novo regulatory pathway for Alzheimer’s treatment. The company plans to submit an amended FDA Q-Submission in Q2 2026 and is finalizing clinical trial design with primary and secondary endpoints informed by FDA guidance.
China collaboration with Professor Yi Tang adds one of the largest single-center real-world data sets using Nexalin’s DIFS non-invasive neurostimulation in aging and dementia populations.
Nexalin Technology (NASDAQ: NXL) will present an investor webinar on April 21, 2026 at 4:15 p.m. ET hosted by RedChip Companies. CEO Mark White will review Nexalin's non-invasive Deep Intracranial Frequency Stimulation (DIFS™) clinical evidence, Gen-3 HALO Clarity headset, Virtual Clinic platform, international regulatory clearances, and U.S. clinical and regulatory initiatives, followed by a live Q&A. Registration is free via RedChip.
Nexalin (NASDAQ: NXL) reported a peer-reviewed BMC Psychiatry pilot showing 21 days of 77.5 Hz, 15 mA DIFS stimulation in six female adolescents with non‑suicidal self‑injury produced statistically significant reductions in depressive symptoms and self‑injury scores.
Changes in TMS‑EEG functional connectivity across Default, Limbic, Salience/Ventral Attention and Control networks were reported; authors call results preliminary and recommend larger randomized trials.
Nexalin (Nasdaq: NXL) announced a planned pivotal, randomized, triple-blinded, sham-controlled 150‑participant trial of HALO™ Clarity for moderate-to-severe insomnia to support a planned de novo submission to the U.S. FDA. The fully decentralized study uses Nexalin’s NeuroCare virtual clinic and EDC, runs four weeks of treatment plus four weeks follow-up, and is conducted with Lindus Health.
The program builds on a prior 120‑participant randomized, double‑blind, placebo‑controlled study published in the Journal of Psychiatric Research and on Nexalin’s Gen‑2 15 mA device regulatory approvals internationally.
Nexalin (Nasdaq: NXL) praised recent bipartisan Congressional actions increasing federal support for deep brain neurostimulation research and said its DIFS™ technology aligns with emerging VA and NIH priorities.
The company noted two appropriations reports signed into law supporting neuromodulation research and an ongoing UC San Diego/San Diego VA study of DIFS™, while H.R. 7091 remains under committee review.
Nexalin (Nasdaq:NXL) launched NeuroCare®, an AI-designed virtual clinic integrated with its new Gen-3 HALO™ headset to deliver home-based Deep Intracranial Frequency Stimulation (DIFS™).
The platform, deployed initially with UC San Diego, supports remote physician monitoring, subscription billing, and clinical trial enrollment for Alzheimer’s, mood disorders, TBI and PTSD.